Chennai Meena

  • Market Cap: Micro Cap
  • Industry: Healthcare Services
  • ISIN: INE889F01017
  • NSEID:
  • BSEID: 523489
INR
37.67
-0.14 (-0.37%)
BSENSE

Jun 03, 03:30 PM

BSE+NSE Vol: 849

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

849 (11.80%) Volume

Shareholding (Mar 2026)

FII

0.00%

Held by 0 FIIs

DII

0.14%

Held by 0 DIIs

Promoter

57.10%

how big is Chennai Meena?

06-Jun-2025

As of Jun 06, Chennai Meenakshi Multispeciality Hospital Ltd has a market capitalization of 23.52 Cr, with net sales of 34.82 Cr and a net profit of -1.37 Cr over the latest four quarters. The standalone balance sheet shows shareholder's funds of -0.33 Cr and total assets of 22.81 Cr.

As of Jun 06, Chennai Meenakshi Multispeciality Hospital Ltd has a market capitalization of 23.52 Cr, classifying it as a Micro Cap company.<BR><BR>As of Jun 06, the company reported a sum of Net Sales for the latest 4 quarters amounting to 34.82 Cr and a Net Profit of -1.37 Cr. This data is based on Standalone financials.<BR><BR>As of Mar 24, the Standalone balance sheet shows Shareholder's Funds of -0.33 Cr and Total Assets of 22.81 Cr.

View full answer

What does Chennai Meena do?

06-Jun-2025

Chennai Meenakshi Multispeciality Hospital Ltd, established in 1990, operates in the healthcare sector as a micro-cap company with a market cap of Rs 23 Cr. As of March 2025, it reported net sales of 9 Cr and a net profit of 0 Cr.

Overview:<BR>Chennai Meenakshi Multispeciality Hospital Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 1990 and was formerly known as Devaki Hospital Limited until its name change in October 2007. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 9 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap value: Rs 23 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 54<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -4.96<BR>- Return on Equity: 98.56%<BR>- Price to Book: -16.83<BR><BR>Contact Details:<BR>- Address: New No 70 Old No 149, Luz Church Road Mylapore Chennai Tamil Nadu : 600004<BR>- Tel: 91-044-42938938<BR>- Email: cmmhospitals@gmail.com<BR>- Website: https://cmmh.in

View full answer

Has Chennai Meena declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Chennai Meena?

03-Jun-2025

Chennai Meena's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Family Care, Gian Lifecare, Vanta Bioscience, and Clinitech Lab. In terms of management risk, growth ratings, and capital structure, they vary from excellent to below average, with Chennai Meena showing a 1-year return of -2.80%.

Peers: The peers of Chennai Meena are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Family Care, Gian Lifecare, Vanta Bioscience, Clinitech Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Clinitech Lab, and Average management risk is noted at Family Care. Below Average management risk is seen at Gian Lifecare, while Vanta Bioscience and Chennai Meena do not qualify. Growth ratings show Good growth at Family Care, Average growth at Poly Medicure, Indegene, and Gian Lifecare, and Below Average growth at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., and Clinitech Lab, with Chennai Meena and Vanta Bioscience not qualifying. Excellent capital structure is noted for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Family Care, and Gian Lifecare, while Good capital structure is observed at Clinitech Lab, and Chennai Meena and Vanta Bioscience do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.17%, while the lowest is Vanta Bioscience at -54.78%. Chennai Meena's 1-year return is -2.80%, which is higher than Vanta Bioscience but lower than Poly Medicure. Additionally, the six-month returns for Family Care, Chennai Meena, Gian Lifecare, Vanta Bioscience, and Clinitech Lab are all negative.

View full answer

Is Chennai Meena overvalued or undervalued?

09-Jun-2025

As of May 31, 2024, Chennai Meena's valuation has shifted from attractive to risky due to negative financial metrics, including a PE ratio of -17.17 and an EV to EBITDA of -30.42, indicating it is overvalued and underperforming compared to peers like Max Healthcare and Apollo Hospitals, as well as the Sensex.

As of 31 May 2024, the valuation grade for Chennai Meena has moved from attractive to risky, indicating a significant deterioration in its financial health. The company appears to be overvalued based on its current metrics, with a PE ratio of -17.17, an EV to EBITDA of -30.42, and a ROCE of -11.43%. These negative ratios suggest that the company is struggling to generate profits and manage its capital effectively.<BR><BR>In comparison to its peers, Chennai Meena's valuation stands out unfavorably. For instance, Max Healthcare has a PE ratio of 100.29, while Apollo Hospitals shows a PE of 69.03, both indicating a much stronger market position. The stark contrast in valuation ratios highlights that Chennai Meena is not only underperforming but also facing significant challenges relative to its competitors. Additionally, the company's stock has underperformed the Sensex over the past year, with a return of -8.52% compared to the Sensex's 7.58%, reinforcing the notion that it is currently overvalued.

View full answer

What is the technical trend for Chennai Meena?

09-Jun-2025

As of May 12, 2025, Chennai Meena's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the weekly MACD and KST.

As of 12 May 2025, the technical trend for Chennai Meena has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages are bearish. The KST reflects a mildly bullish weekly trend but is mildly bearish monthly. The Dow Theory shows a mildly bullish weekly trend with no trend on the monthly. Overall, the current technical stance is mildly bearish, influenced primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the MACD and KST on the weekly chart.

View full answer

Who are in the management team of Chennai Meena?

16-Jul-2025

As of March 2023, the management team of Chennai Meena consists of R Gomathi as Managing Director and K. Meyyanathan, N. Rajkumar, and Jayanthi Radhakrishnan as Independent Directors.

As of March 2023, the management team of Chennai Meena includes the following individuals:<BR><BR>1. R Gomathi - Managing Director<BR>2. K. Meyyanathan - Independent Director<BR>3. N. Rajkumar - Independent Director<BR>4. Jayanthi Radhakrishnan - Independent Director<BR><BR>R Gomathi serves as the Managing Director, while the other three members hold positions as Independent Directors.

View full answer

Who are the top shareholders of the Chennai Meena?

17-Jul-2025

The top shareholders of Chennai Meena are Jayanthi Radhakrishnan with 25.59%, followed by public shareholder Vijayan Abinaya at 10.06%. Individual investors own 60.51%, with no pledged promoter holdings or foreign institutional investors.

The top shareholders of Chennai Meena include Jayanthi Radhakrishnan, who holds the highest stake at 25.59%. The highest public shareholder is Vijayan Abinaya, with a holding of 10.06%. Additionally, individual investors collectively own 60.51% of the company. There are no pledged promoter holdings or foreign institutional investors involved, and mutual funds hold a small percentage through one scheme at 0.14%.

View full answer

How has been the historical performance of Chennai Meena?

14-Nov-2025

Chennai Meena's historical performance shows declining net sales and profits, with revenue dropping from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25, and a shift from profit to loss in operating profit and net profit. Despite these challenges, total liabilities and cash flow from operations remained stable.

Answer:<BR>The historical performance of Chennai Meena shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Chennai Meena's net sales decreased from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25, reflecting a decline in revenue. The total operating income followed a similar trend, dropping from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25. The company experienced an operating profit (PBDIT) decline, moving from 3.35 Cr in Mar'23 to a loss of 0.21 Cr in Mar'25. Consequently, the profit before tax also fell from 1.28 Cr in Mar'23 to a loss of 1.43 Cr in Mar'25, leading to a profit after tax decline from 0.89 Cr to a loss of 1.37 Cr in the same period. The company's total liabilities remained relatively stable, with a slight decrease from 22.81 Cr in Mar'24 to 22.51 Cr in Mar'25. Cash flow from operating activities remained consistent at 2.00 Cr from Mar'22 to Mar'25, while the closing cash and cash equivalents were stable at 2.00 Cr in Mar'25. Overall, Chennai Meena's financial performance indicates challenges in profitability despite stable cash flow and liabilities.

View full answer

When is the next results date for Chennai Meenakshi Multispeciality Hospital Ltd?

14-May-2026

The next results date for Chennai Meenakshi Multispeciality Hospital Ltd is 25 May 2026.

The next results date for Chennai Meenakshi Multispeciality Hospital Ltd is scheduled for 25 May 2026.

View full answer

Are Chennai Meenakshi Multispeciality Hospital Ltd latest results good or bad?

26-May-2026

Chennai Meenakshi Multispeciality Hospital Ltd's latest results are concerning, showing a net loss of ₹0.02 crore in Q4 FY26 despite a 6.98% revenue increase, marking the second consecutive quarterly loss and highlighting ongoing operational challenges and a negative net worth.

Chennai Meenakshi Multispeciality Hospital Ltd's latest results indicate a challenging financial situation. In Q4 FY26, the company reported a net loss of ₹0.02 crore, a significant decline from a profit of ₹0.31 crore in the same quarter last year. While revenue increased by 6.98% year-on-year to ₹9.81 crore, this growth did not translate into profitability, marking the second consecutive quarterly loss for the company.<BR><BR>The operating margin also contracted to 2.55%, down 127 basis points from the previous year, highlighting ongoing operational challenges. Additionally, the company has a negative net worth, with a book value per share of negative ₹2.53, raising serious concerns about its financial stability and ability to invest in necessary improvements.<BR><BR>Overall, the results reflect a company struggling with fundamental operational issues, and the volatility in profitability raises questions about the sustainability of its business model.

View full answer

Should I buy, sell or hold Chennai Meenakshi Multispeciality Hospital Ltd?

27-May-2026

Why is Chennai Meenakshi Multispeciality Hospital Ltd falling/rising?

02-Jun-2026

As of 02-Jun, the stock price of Chennai Meenakshi Multispeciality Hospital Ltd is declining, currently at 37.81, reflecting a 3.79% decrease. The stock has underperformed its sector and the benchmark Sensex, with a year-to-date decline of 17.79%, indicating reduced investor interest and short-term price weakness.

As of 02-Jun, the stock price of Chennai Meenakshi Multispeciality Hospital Ltd is falling, currently at 37.81, which reflects a decrease of 1.49 or 3.79%. This decline is evident in the stock's performance today, where it underperformed its sector by 1.28%. Over the past week, the stock has decreased by 1.56%, while the benchmark Sensex fell by 1.79%, indicating that the stock is not only declining but doing so at a slightly better rate than the overall market.<BR><BR>Additionally, the stock has shown a year-to-date decline of 17.79%, compared to a 12.40% drop in the Sensex, further highlighting its underperformance. The moving averages indicate that while the stock is higher than the 20-day and 50-day moving averages, it is lower than the 5-day, 100-day, and 200-day moving averages, suggesting a short-term weakness in price momentum.<BR><BR>Investor participation appears to be decreasing as well, with a delivery volume of 978 on June 1, which is down by 16.51% against the 5-day average. This drop in trading volume may signal reduced interest from investors, contributing to the stock's price decline. Overall, these factors collectively explain the falling price of Chennai Meenakshi Multispeciality Hospital Ltd.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of 13.71% and Operating profit at 0% over the last 5 years
  • The company has a negative book value of Rs 3.07 crore
2

Flat results in Mar 26

3

Risky - Negative EBITDA

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Healthcare Services

stock-summary
Market cap

INR 28 Cr (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

58

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.76

stock-summary
Return on Equity

37.46%

stock-summary
Price to Book

-9.44

Revenue and Profits:
Net Sales:
10 Cr
(Quarterly Results - Mar 2026)
Net Profit:
0 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.59%
0%
-1.59%
6 Months
-16.29%
0%
-16.29%
1 Year
22.15%
0%
22.15%
2 Years
15.8%
0%
15.8%
3 Years
75.21%
0%
75.21%
4 Years
77.27%
0%
77.27%
5 Years
157.84%
0%
157.84%

Chennai Meena for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Compliances-Reg.24(A)-Annual Secretarial Compliance

30-May-2026 | Source : BSE

In continuation to the Letter submitted by Chennai Meenakshi Multispeciality Hospital Limited bearing reference No. CMMH/BSEE/2026-27/06 dated April 21 2026. We would like to inform you that pursuant to Regulation 15(2) of SEBI (LODR) Regulations 2015 the compliance with the Corporate Governance provisions as specified in Reg 17 17A 18 19 20 21 22 2324 24A252627 and clauses (b) to (i) of sub-regulations (2) of Regulation 46 and para CD and E of Schedule V shall not apply in respect of our company as the paid up equity share capital of does not exeed Rupees ten crores and net worth does not exceed rupees twenty five crores as on the last day of the previous financial year i.e. 31st March 2026.

Announcement under Regulation 30 (LODR)-Newspaper Publication

29-May-2026 | Source : BSE

Pursuant to Regulation 47 and other applicable provisions of SEBI (LODR) Regulations 2015 please find enclosed herewith copies of the newspaper advertisement published by the Company regarding the Audited financial results for Quarter & financial year ended 31st March 2026. The audited financial results were considered approved and taken on record by the Board of Directors of the Company at its meeting held on 25th May 2026. The advertisement published on 26th May 2026 in Financial Express-English and Makkal Kural -Tamil. The newspaper clipping are also being made available on the website of the Company at www.cmmh.in.

Board Meeting Outcome for The Approved Audited Financial Results Along With Audit Report Cash Flow Statement For The Year Ended 31St March 2026 And Declaration On The Report Of Auditors With Unmodified Opinion On 25Th May 2026

25-May-2026 | Source : BSE

This is to intimate that the Board of Directors of the Company at its meeting held on Monday May 25 2026 at the registered office of the Company have inter alia approved the Audited Financial Results for the quarter and financial year ended 31st March 2026. The Board of Directors have not recommended any Dividend for the year 2025-26. The approved Audited Financial Results along with audit report Cash Flow Statement for the year ended 31st March 2026 and declaration on the report of auditors with unmodified opinion are enclosed with this letter. Further we would like to inform that the financial results will be published in the newspapers pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The financial results are also available on the Companys website - www.cmmh.in. The meeting commenced at 12:00 Hours and concluded at 15:00 Hours.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
13.71%
EBIT Growth (5y)
-25.47%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
0.25
Net Debt to Equity (avg)
-1.76
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.14%
ROCE (avg)
7.95%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
58
Price to Book Value
-9.15
EV to EBIT
-24.08
EV to EBITDA
-33.47
EV to Capital Employed
14.43
EV to Sales
0.90
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-59.91%
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 1 Schemes (0.14%)

FIIs

Held by 0 FIIs

Promoter with highest holding

Jayanthi Radhakrishnan (25.59%)

Highest Public shareholder

Mahendra Girdharilal Wadhwani (2.65%)

Individual Investors Holdings

39.83%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 7.68% vs -3.80% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 96.30% vs -460.00% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.81",
          "val2": "9.11",
          "chgp": "7.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.25",
          "val2": "-0.33",
          "chgp": "175.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.23",
          "val2": "0.22",
          "chgp": "4.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.02",
          "val2": "-0.54",
          "chgp": "96.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "2.55%",
          "val2": "-3.62%",
          "chgp": "6.17%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 7.73% vs -9.52% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 44.34% vs -1,866.67% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.12",
          "val2": "16.82",
          "chgp": "7.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.22",
          "val2": "-0.17",
          "chgp": "-29.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.45",
          "val2": "0.46",
          "chgp": "-2.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.59",
          "val2": "-1.06",
          "chgp": "44.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1.21%",
          "val2": "-1.01%",
          "chgp": "-0.20%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 6.16% vs -10.50% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 33.14% vs -8,550.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "27.23",
          "val2": "25.65",
          "chgp": "6.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.55",
          "val2": "-0.55",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.67",
          "val2": "0.69",
          "chgp": "-2.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-1.13",
          "val2": "-1.69",
          "chgp": "33.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2.02%",
          "val2": "-2.14%",
          "chgp": "0.12%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 6.38% vs -8.85% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 18.25% vs -218.60% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "37.04",
          "val2": "34.82",
          "chgp": "6.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.28",
          "val2": "-0.21",
          "chgp": "-33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "0.91",
          "chgp": "-1.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-1.12",
          "val2": "-1.37",
          "chgp": "18.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-0.76%",
          "val2": "-0.60%",
          "chgp": "-0.16%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
9.81
9.11
7.68%
Operating Profit (PBDIT) excl Other Income
0.25
-0.33
175.76%
Interest
0.23
0.22
4.55%
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.02
-0.54
96.30%
Operating Profit Margin (Excl OI)
2.55%
-3.62%
6.17%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 7.68% vs -3.80% in Dec 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 96.30% vs -460.00% in Dec 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
18.12
16.82
7.73%
Operating Profit (PBDIT) excl Other Income
-0.22
-0.17
-29.41%
Interest
0.45
0.46
-2.17%
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.59
-1.06
44.34%
Operating Profit Margin (Excl OI)
-1.21%
-1.01%
-0.20%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 7.73% vs -9.52% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is 44.34% vs -1,866.67% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
27.23
25.65
6.16%
Operating Profit (PBDIT) excl Other Income
-0.55
-0.55
Interest
0.67
0.69
-2.90%
Exceptional Items
0.00
0.00
Standalone Net Profit
-1.13
-1.69
33.14%
Operating Profit Margin (Excl OI)
-2.02%
-2.14%
0.12%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 6.16% vs -10.50% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is 33.14% vs -8,550.00% in Dec 2024

Annual Results Snapshot (Standalone) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
37.04
34.82
6.38%
Operating Profit (PBDIT) excl Other Income
-0.28
-0.21
-33.33%
Interest
0.90
0.91
-1.10%
Exceptional Items
0.00
0.00
Standalone Net Profit
-1.12
-1.37
18.25%
Operating Profit Margin (Excl OI)
-0.76%
-0.60%
-0.16%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 6.38% vs -8.85% in Mar 2025

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2026 is 18.25% vs -218.60% in Mar 2025

stock-summaryCompany CV
About Chennai Meenakshi Multispeciality Hospital Ltd stock-summary
stock-summary
Chennai Meenakshi Multispeciality Hospital Ltd
Micro Cap
Healthcare Services
Chennai Meenakshi Multispeciality Hospital Limited, formerly known as Devaki Hospital Limited, was incorporated in 1990. The Company name was changed from Devaki Hospital Limited to Chennai Meenakshi Multispeciality Hospital Limited in October, 2007. It is a 100-bedded hospital located in the heart of Chennai at Mylapore. The hospital has an infrastructure comprising of around 105 Beds including ICU Beds, Operating Theatre, a modern dialysis Unit besides a host of other facilities.
Company Coordinates stock-summary
Company Details
New No 70 Old No 149, Luz Church Road Mylapore Chennai Tamil Nadu : 600004
stock-summary
Tel: 91-044-42938938
stock-summary
cmmhospitals@gmail.com
Registrar Details
Cameo Corporate Services Ltd , Subramanian Buildings No 1 , Club House Road, Chennai